panelists discuss access to car-t for patients with myeloma
Published 1 year ago • 89 plays • Length 5:03Download video MP4
Download video MP3
Similar videos
-
7:55
real-world car-t outcomes, use of ide-cel, cilta-cel for myeloma
-
8:14
bispecific versus car t-cell therapy for myeloma and bridging therapy needs for car-t
-
3:47
what is car t-cell therapy?
-
49:59
car t-cell therapy: multiple myeloma
-
15:50
understanding car t therapy: a groundbreaking approach to myeloma treatment
-
2:05
car t-cell therapy as early treatment for multiple myeloma - blood cancers video library
-
1:49
how can myeloma patients access car t-cell therapy clinical trials?
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:12
optimizing car-t therapy for patients with multiple myeloma in the real-world
-
1:00
side effects of car t cell therapy
-
31:00
car t-cells multiple myeloma: adam sperling, md, phd
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
7:42
car t-cell therapy for patients with late relapsed/refractory myeloma - blood cancers video library
-
1:45
car t-cells in myeloma: patients’ perspective
-
0:54
car t-cell therapy treating myeloma
-
9:48
the use of car t-cells in multiple myeloma
-
1:29
ash annual meeting: car-t and multiple myeloma
-
4:14
challenges with the real-world use of car-t therapy in multiple myeloma
-
13:57
uams offering revolutionary car t-cell therapy for myeloma patients